Douglas Yee, MD
- John H. Kersey Chair in Cancer Research, University of Minnesota.
- Director, Masonic Cancer Center, University of Minnesota
Douglas Yee, MD, holds the John H. Kersey Chair in Cancer Research at the University of Minnesota. He was previously co-leader of the women’s cancer program. He was named director of the Masonic Cancer Center, University of Minnesota in 2007. Prior to coming to Minnesota, he held faculty positions at Georgetown University Medical Center and the University of Texas Health Science Center at San Antonio.
Atezolizumab (Tecentriq) is an immunotherapy that was granted accelerated approval by the Food and Drug Administration in March 2019 to treat metastatic triple-negative breast cancer that expresses the PD-L1 protein and was voluntarily withdrawn in 2021 because follow-up research failed to confirm the initial promising results that prompted the accelerated approval.
Stage IV breast cancer prognosis
Prognosis means the likely outcome or course of a disease. If you’ve been diagnosed with stage IV metastatic breast cancer (MBC), you may have already learned that it means being in treatment for life. It’s completely understandable to want to know how long that really is.